Also consistent with bone marrow-derived MSCs (Figure 2E), inhibition of TGF-β activity enhances adipogenesis in prostate cancer-derived MSCs (Figure 5C, 5E, Supplementary Table 1) with AR inhibition having a small additive effect in this context (Figure 5D, Supplementary Tables 3, 4). Here, TGFB1 is linked to prostate cancer.